Lilly drops PD-L1/TIM-3 bispecific from clinical pipeline

Eli Lilly has another anti-TIM-3 drug in its pipeline. (Eli Lilly/LinkedIn)

Eli Lilly has dropped (PDF) a PD-L1/TIM-3 bispecific antibody from its clinical pipeline. The asset moved into a phase 1 advanced solid tumor trial late last year but was culled from the pipeline before delivering final data.

Lilly, Roche, Novartis, Tesaro and other companies have progressed anti-TIM-3 drugs into the clinic in recent years on the strength of evidence that the co-inhibitory molecule marks exhausted T cells in the tumor microenvironment. As T-cell exhaustion limits responses to PD-1/L-1 drugs, the function of TIM-3 raised hopes that the target can help overcome primary and acquired resistance to checkpoint inhibitors.  

Those hopes led Lilly to design a PD-L1/TIM-3 bispecific and start testing it in humans last year. Lilly and its collaborators discussed the trial last month at the 2019 American Society of Clinical Oncology annual meeting. But over the following weeks, Lilly decided to dump the molecule, leading to its removal from its pipeline in a R&D update today.


Industry Insight Survey: Direct-to-Patient Distribution of Clinical Supplies

This industry survey seeks to gain insight on trial sponsors' perspective on offering a DTP option and their current level of awareness and understanding of any factors that may influence their ability to do so. The first 50 qualified respondents will receive a $5 Amazon gift card.

The move seemingly signals the end for the PD-L1/TIM-3 bispecific at Lilly, but the company retains an interest in the concept that attracted it to the molecule. Lilly began testing an anti-TIM-3 antibody, LY3321367, in humans in 2017, putting it ahead of the bispecific in development. A phase 1 trial of LY3321367 as a monotherapy and in combination with a PD-L1 antibody is continuing. 

Most of the other companies with anti-TIM-3 drugs in the clinic are pursuing similar combination strategies to Lilly. Roche is one of the notable exceptions. The Swiss pharma moved its PD-1/TIM-3 drug, RO7121661, into the clinic around the same time Lilly began enrolling subjects in a trial of its now-axed bispecific.

Lilly disclosed the removal of the drug from its pipeline alongside news of the axing of another bispecific. The second drug to get the chop was an IL-23/CGRP bispecific antibody that Lilly saw as a potential treatment for autoimmune diseases such as inflammatory bowel disease and psoriatic arthritis.

Suggested Articles

Biogen stunned the biotech world Tuesday when it said it would file aducanumab for approval. Now that the dust has settled, what are analysts saying?

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts.

Upselling customers on high-tech breast cancer screenings is just one way the 3D mammography industry aggressively promotes its product.